Literature DB >> 19805684

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

Todd A Theman1, Tristan L Hartzell, Indranil Sinha, Kathleen Polson, Jeffrey Morgan, George D Demetri, Dennis P Orgill, Suzanne George.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19805684     DOI： 10.1200/JCO.2008.21.6473

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  Extravasation of chemotherapy.

Authors:  Seppo W Langer
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

2.  A midline for oxaliplatin infusion: the myth of safety devices.

Authors:  Ben Masters; Tamas Hickish; Esther Uña Cidon
Journal:  BMJ Case Rep       Date:  2014-06-05

3.  Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.

Authors:  Ursula Pluschnig; Werner Haslik; Günther Bayer; Afschin Soleiman; Rupert Bartsch; Wolfgang Lamm; Günther G Steger; Christoph C Zielinski; Robert M Mader
Journal:  Support Care Cancer       Date:  2014-11-30       Impact factor: 3.603

4.  Determination of Extravasation Effects of Nal-Iri and Trabectedin and Evaluation of Treatment Options for Trabectedin Extravasation in a Preclinical Animal Model.

Authors:  Omar Keritam; Viktoria Juhasz; Christian Schöfer; Christiane Thallinger; Marie-Bernadette Aretin; Gernot Schabbauer; Johannes Breuss; Matthias Unseld; Pavel Uhrin
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

5.  Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

Authors:  Thomas Schmitt; Eva Keller; Sascha Dietrich; Patrick Wuchter; Anthony D Ho; Gerlinde Egerer
Journal:  Mar Drugs       Date:  2010-10-13       Impact factor: 5.118

6.  Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.

Authors:  Stefan M Willems; Yvonne M Schrage; Inge H Briaire-de Bruijn; Karoly Szuhai; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

7.  Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.

Authors:  Mathias Hoiczyk; Florian Grabellus; Lars Podleska; Marit Ahrens; Benjamin Schwindenhammer; Georg Taeger; Christoph Pöttgen; Martin Schuler; Sebastian Bauer
Journal:  Int J Oncol       Date:  2013-05-02       Impact factor: 5.650

Review 8.  Extravasation emergencies: state-of-the-art management and progress in clinical research.

Authors:  Ursula Pluschnig; Werner Haslik; Rupert Bartsch; Robert M Mader
Journal:  Memo       Date:  2016-12-05

9.  Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Authors:  Michiel C Verboom; Jan Ouwerkerk; Neeltje Steeghs; Jacob Lutjeboer; J Martijn Kerst; Winette T A van der Graaf; Anna K L Reyners; Stefan Sleijfer; Hans Gelderblom
Journal:  Clin Sarcoma Res       Date:  2017-01-31

10.  Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.

Authors:  Robin L Jones; Robert G Maki; Shreyaskumar R Patel; George Wang; Tracy A McGowan; Waleed S Shalaby; Roland E Knoblauch; Margaret von Mehren; George D Demetri
Journal:  Cancer       Date:  2019-09-10       Impact factor: 6.860
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.